infections in patients w/ haematological malignancy Flashcards

1
Q

cause of death after stem cell transplants

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

supportive measures aimed at reducing risk of sepsis in haematological malignancy

A
prophylaxis
growth factors e.g. G-CSF
stem cell rescue/transplant
protective environment e.g. laminar flow rooms 
IV immunoglobulin replacement 
vaccination
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

prophylaxis to reduce risk of sepsis in haematological malignancy

A

abx - ciprofloxacin
anti-fungal - fluconazole, itraconazole
anti-viral - aciclovir
PJP - co-trimoxazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

who is at highest risk of neutropenic infection

A

cause of neutropenia (marrow failure > immune destruction)

degree of neutropenia

  • <0.5x10^9/L - significant risk
  • <0.2x10^9/L - highest risk

duration of neutropenia
- >7days - high risk
(AML therapy and stem cell transplantation produces profound neutropenia ~14-21 days)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

why do marrow failure pts have higher risk of neutropenic infection than immune destruction pts

A

bone marrow failure = failure of production
- only neutrophils left are old and dying and less functional

immune destruction - bone marrow is still able to respond to infection and produce more neutrophils which are able to fight the infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

additional risk factors for infection

A

disrupted skin/mucosal surfaces

altered flora/abx resistance

lymphopenia

monocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

disrupted skin/mucosal surfaces examples

A

hickman line, venflons

mucositis affecting GI tract

GVHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

altered flora and antibiotic resistance - how can it occur

A

prophylactic abx can save lives in severe neutropenia but also have -ve side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

lymphopenia as an additional risk factor for infection - what causes it

A

common in lymphoma

result of treatment e.g. fludarabine, ATG

stem cell transplantation, GVHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what causes monocytopenia

A

hairy cell leukaemia

chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

bacterial causes of febrile neutropenia

A

gram +ve - 60-70%
gram -ve bacilli - 30-40%

patterns may now relate to abx prophylaxis, emerging infections, use of lines etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what types of gram +ve bacteria infections are seen

A

staphylococci: MSSA, MRSA, coagulase -ve
streptococci: viridans

enterococcus faecalis/faecium
corynebacterium spp
bacillus spp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what types of gram -ve bacterial infections are seen

A

escherichia coli

Klebsiella spp: ESBL

psuedomonas aeruginosa

enterobacter spp
acinetobacter spp
citrobacter spp
stenotrophomonas maltophilia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

possible sites of infection

A
resp tract
GI - typhlitis 
dental sepsis 
mouth ulcers
skin sores
exit site of central venous catheters
perianal (avoid PRs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

presentation of neutropenic sepsis

A

fever w/ no localising signs - single reading of >38.5 or 38 on two readings 1hr apart

rigors
chest infection/pneumonia 
skin sepsis - cellulitis
UTI
septic shock
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is crucial in sepsis

A

early recognition and treatment

consider it in any one who has recently had chemotherapy (even up to 6 weeks after last dose)

17
Q

what is severe sepsis/septic shock

A

signs of systemic inflammation (SIRS) AND presumed organ infection and organ dysfunction

18
Q

what is the sepsis 6

A

GIVE:

  • high flow oxygen
  • appropriate IV abx within 1hr
  • IV fluid resus

TAKE:

  • blood cultures, other cultures, consider source control
  • serum lactate concentration
  • UO
19
Q

why is important to administer abx early in sepsis

A

every hr delay increases chance of mortality by 8%

20
Q

investigation of a neutropenic fever

A

hx and examination

blood cultures - hickman line and peripheral

CXR

throat swab and other clinical sites of infection

sputum if productive

FBC, renal function, LFTs, coagulation screen

21
Q

management of neutropenic sepsis

A

resus - ABC and sepsis 6

broad spectrum IV abx

  • tazocin and gentamicin
  • if gram +ve identified: add vancomycin or

if no response at 72hrs: add IV antifungal treatment
- capsofungin (empiric therapy)

CT chest/abdo/pelvis to look for source

modify treatment based on culture results

22
Q

fungal infection in immunocompromised patients

A

candida spp e.g. aspergillus

life threatening, deep seated infection

lung, liver, sinuses, brain

23
Q

what contributes to the risk of fungal infection

A

monocytopenia and monocyte dysfunction

24
Q

where is fungal infection most commonly seen

A

in pts who’ve either had transplant or treatment for acute leukaemia

25
therapy of fungal infections
empirical - echinocandins e.g. capsofungin, anidulafungin aspergillus - voriconazole, isavuconazole (can both be given IV/oral) moulds - liposomal amphotericin (ambisome)
26
infections in severely lymphopenic patients - when does it happen
stem cell transplant recipients, esp allogenic recipients of total body irradiation GVHD use of nucleoside analogues (fludarabine) or ATG lymphoid malignancy e.g. lymphoma, CLL, ALL
27
types of infections seen in severely lymphopenic patients
pneumonitis viral fungal atypical mycobacteria
28
pneumonitis infections seen in severely lymphopenic patients
- pneumocystis jirovecii (PJP) - CMV - can also cause GI infection - RSV
29
viral infections seen in severely lymphopenic patients
- shingels (VZV) - mouth ulcers (HSV) - adenovirus - EBV (PTLD) - SARS-CoV2
30
what is PTLD
post-transplantive lymphoproliferative disorders driven entirely through activation of EBV happens in pts who are immunocompromised after transplants (bone marrow/stem cell)
31
fungal infections seen in severely lymphopenic patients
candida aspergillus murormycosis
32
atypical mycobacteria infections seen in severely lymphopenic patients
skin lesions pulmonary and hepatic involvement
33
therapy for viral infections - PJP
high dose trimoxazole IV initially then switch to oral if patients can tolerate it
34
therapy for viral infections - CMV
ganciclovir, foscarnet both IV oral preparation: valganciclovir (mostly for post-allogenic transplant pts where you are monitoring for CMV reactivation)
35
therapy for viral infections - HSV1, VZV
aciclovir treat promptly to reduce risk of postherpetic neuralgia
36
therapy for viral infections - influenza A/B
oseltamivir zanamivir
37
therapy for viral infections - adenovirus
cidofovir IV
38
therapy for viral infections - RSV
ribavirin
39
therapy for viral infections - not anti-viral
immunoglobulin replacement e.g. post alloSCT